Childhood Kidney Diseases

Korean Society of Pediatric Nephrology (대한소아신장학회)
권호 표지
DOI QR코드

DOI QR Code

Hypomagnesemia as a reversible complication of cyclosporine in pediatric nephrotic syndrome: a case report

  • Quang Chi Ngo (Department of Pediatrics, Faculty of Medicine, Can Tho University of Medicine and Pharmacy) ;
  • Hung Do Tran (Department of Microbiology, Faculty of Nursing and Medical Technology, Can Tho University of Medicine and Pharmacy) ;
  • Ngoc Bao Thi Nguyen (Department of Cardiology and Nephrology, Can Tho Children's Hospital) ;
  • Tham Hong Thi Nguyen (Department of Pediatrics, Faculty of Medicine, Can Tho University of Medicine and Pharmacy) ;
  • Trang Thuy Mai (Department of Pediatrics, Faculty of Medicine, Can Tho University of Medicine and Pharmacy)
  • Received : 2025.06.11
  • Accepted : 2025.07.04
  • Published : 2025.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Calcineurin inhibitors remain a cornerstone in the treatment of steroid-resistant nephrotic syndrome (SRNS) in pediatric patients. Hypomagnesemia, a clinically relevant yet frequently neglected complication of calcineurin inhibitors like cyclosporine, may exacerbate hypokalemia and induce neuromuscular symptoms such as tetany, challenging patient management. However, serum magnesium is not routinely monitored in many clinical settings. A 46-month-old girl with SRNS had been receiving highdose cyclosporine for over 1 year. She was admitted with vomiting, diarrhea, generalized edema, and hypovolemic shock. After stabilization, she developed persistent hypokalemia refractory to supplementation, despite normal renal function and basic electrolyte panel. On hospital day 10, carpal-type tetany prompted the first measurement of serum magnesium, revealing severe hypomagnesemia (0.14 mmol/L). Cyclosporine was temporarily withheld, and intravenous then oral magnesium was administered. Tetany resolved within 48 hours, and both serum magnesium and potassium levels normalized. This case highlights the risk of delayed recognition of symptomatic hypomagnesemia during prolonged cyclosporine therapy in children. Tetany was the first neurological manifestation of a preventable complication. Current guidelines lack clear recommendations regarding magnesium surveillance in pediatric SRNS receiving cyclosporin. This case underscores a critical gap in practice and calls for the integration of magnesium monitoring into standard care for this vulnerable population.

Keywords

Acknowledgement

We sincerely thank Can Tho University of Medicine and Pharmacy for their professional support and valuable feedback during the preparation of this case report.

References

  1. Trautmann A, Vivarelli M, Samuel S, Gipson D, Sinha A, Schaefer F, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 2020;35:1529-61.
  2. Adomako EA, Yu ASL. Magnesium disorders: core curriculum 2024. Am J Kidney Dis 2024;83:803-15.
  3. Ledeganck KJ, Boulet GA, Horvath CA, Vinckx M, Bogers JJ, Van Den Bossche R, et al. Expression of renal distal tubule transporters TRPM6 and NCC in a rat model of cyclosporine nephrotoxicity and effect of EGF treatment. Am J Physiol Renal Physiol 2011;301:F486-93.
  4. Ledeganck KJ, De Winter BY, Van den Driessche A, Jurgens A, Bosmans JL, Couttenye MM, et al. Magnesium loss in cyclosporine-treated patients is related to renal epidermal growth factor downregulation. Nephrol Dial Transplant 2014;29:1097-102.
  5. Ray S, Park KW. Movement disorders and other neurologic impairment associated with hypomagnesemia: a systematic review. Neurol Clin Pract 2023;13:e200202.
  6. Thompson CB, June CH, Sullivan KM, Thomas ED. Association between cyclosporin neurotoxicity and hypomagnesaemia. Lancet 1984;2:1116-20.
  7. Tong GM, Rude RK. Magnesium deficiency in critical illness. J Intensive Care Med 2005;20:3-17.
  8. Arora N, Jefferson J. Electrolyte and acid-base disorders. In: Papadakis MA, McPhee SJ, Rabow MW, McQuaid KR, Gandhi M, editors. Current medical diagnosis & treatment 2024. 63rd ed. McGraw Hill; 2024. p. 880-909.
  9. Uslu Gokceoglu A, Comak E, Dogan CS, Koyun M, Akbas H, Akman S. Magnesium excretion and hypomagnesemia in pediatric renal transplant recipients. Ren Fail 2014;36:1056-9.
  10. Noe A, Cappelli B, Biffi A, Chiesa R, Frugnoli I, Biral E, et al. High incidence of severe cyclosporine neurotoxicity in children affected by haemoglobinopaties undergoing myeloablative haematopoietic stem cell transplantation: early diagnosis and prompt intervention ameliorates neurological outcome. Ital J Pediatr 2010;36:14.
  11. Wang Y, Zheng Y, Wen J, Ren J, Yuan X, Yang T, et al. Cyclosporine A-related neurotoxicity after haploidentical hematopoietic stem cell transplantation in children with hematopathy. Ital J Pediatr 2021;47:83.
  12. Taque S, Peudenier S, Gie S, Rambeau M, Gandemer V, Bridoux L, et al. Central neurotoxicity of cyclosporine in two children with nephrotic syndrome. Pediatr Nephrol 2004;19:276-80.
  13. Vasudevan A, Thergaonkar R, Mantan M, Sharma J, Khandelwal P, Hari P, et al. Consensus guidelines on management of steroid-resistant nephrotic syndrome. Indian Pediatr 2021;58:650-66.
  14. National Library of Medicine. NEORAL® (cyclosporine): prescribing information [Internet]. Novartis Pharmaceuticals Corporation; 2025 [cited 2025 May 29]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94461af3-11f1-4670-95d4-2965b9538ae3
  15. Nguyen TH, Le VTT, Quach DN, Diep HG, Nguyen NK, Lam AN, et al. Drug-related problems in prescribing for pediatric outpatients in Vietnam. Healthcare (Basel) 2021;9:327.